Investment Highlights
- Significant TAM Opportunity
- Breast Cancer Market: $38.35B in 2023 → $89.67B by 2030
- Ovarian Cancer Market: High unmet need – Avastin alone generates $3B/year revenue from tumor-vascular targeting.
- Robust Pipeline and Strong Clinical Data
- Elite Research Collaborations (Cleveland Clinic and Moffitt Cancer Center)
- Capital Efficient Business Model Total Burn Last Fiscal Year was $7 Million
- Strong Balance Sheet $16M cash & short-term investments and no debt (4/30/25)
- Clean Capital Table No warrants and no preferred stock
- Strong Consistent Insider Buying
Company Information
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer designed specifically for solid tumors, potentially overcoming traditional CAR-T limitations in safe and unique targeting, anti-angiogenic effects, and localized delivery. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, a novel type of CAR-T designed specifically for solid tumors, overcoming traditional CAR-T limitations in trafficking, tumor infiltration, and microenvironment resistance.
The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent triple negative breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. This molecular mechanism of action is a novel approach that has not been tried before.
Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.
Partners and Endorsements
"Triple negative breast cancer is the form of the disease for which we have the least effective treatments," said G. Thomas Budd, M.D. of Cleveland Clinic's Cancer Institute and principal investigator of the Phase 1 breast cancer vaccine study. "Long term, we are hoping that Anixa’s breast cancer vaccine can be a true preventive vaccine that would be administered to individuals who are cancer-free to prevent them from developing this highly aggressive disease."
Dr. Conejo-Garcia, stated, "Anixa and its development partner, Moffitt Cancer Center, have been working together to advance this ovarian cancer therapy and we are excited about the clinical results to date—with the treatment appearing to be safe and well-tolerated, and some patients exhibiting tumor necrosis. If this therapeutic approach is successful, this could enable a major shift in the overall treatment paradigm for ovarian cancer."
Clinical Programs
CAR-T for Ovarian Cancer
- 9 patients dosed (as of May 2025)
- IP delivery advantage: local targeting, reduced toxicity
- One patient alive >24 months, one patient alive >12 months, and several others have outlived their life expectancy.
Breast Cancer Vaccine
- 35 patients dosed through Phase 1 cohorts
- 70% achieved protocol-specific immune response
- Combination with Keytruda showed that vaccine and Keytruda could be used without causing additional adverse side effects
- Phase 2 starts in the near future in neo-adjuvant setting
Near-Term Catalysts
- Breast Cancer Vaccine Discussions with the FDA
- Ovarian CAR-T multiple cohort updates – H2 2025
- Additional preclinical program data – Ongoing
Advisory Boards
Renowned doctors in oncology research
